Rich Insights into the Systemic Lupus Erythematosus Market, Epidemiology Segmentation, Pipeline therapies and Major Players in the Industry

Rich Insights into the Systemic Lupus Erythematosus Market, Epidemiology Segmentation, Pipeline therapies and Major Players in the Industry

DelveInsight’s “Systemic Lupus Erythematosus (SLE)“ report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Highlights from the Systemic Lupus Erythematosus  Market Report:

• Total diagnosed prevalent cases of SLE in the 7MM was found to be 484,213 in 2017. Among all the countries, the estimates show a higher population of SLE in the United States with over 259,000 cases in 2017.
• According to DelveInsight estimates, among the 7MM, Japan had the lowest diagnosed prevalent population of SLE in 2017. The appearance of the SLE is independent of the age, although the onset is usually observed in persons aged 20-30 years.
• Among the EU5 countries, the UK had the highest diagnosed prevalent population of SLE, followed by Italy. On the other hand, Spain had the lowest SLE prevalent population
• Key Pipeline Therapies in the Systemic Lupus Erythematosus market include Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), ILT-101 (ILTOO Pharma), BIIB059 (Biogen), Efavaleukin alfa (Amgen), Dapirolizumab pegol (UCB Pharma/Biogen), IFNα Kinoid (Neovacs), Cenerimod (Idorsia Pharmaceuticals), Avizakimab (Boston Pharmaceuticals), Lulizumab pegol , Iberdomide (Bristol-Myers Squibb), XmAb5871 (Xencor), and others.
• Major Players involved in the SLE market are AstraZeneca, ImmuPharma, Eli Lilly, ILTOO Pharma, Biogen, Amgen, UCB Pharma, Neovacs, Idorsia Pharmaceuticals, Boston Pharmaceuticals, Bristol-Myers Squibb, Xencor, among others.

To learn more, request for Sample@ Systemic Lupus Erythematosus Market Insights

The Systemic Lupus Erythematosus market report offers available therapies, treatment landscape, emerging therapies, changing market landscape, individual market share of pipeline therapies, SLE market drivers, and market barriers, SLE market size during the study period 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).

Systemic Lupus Erythematosus: Disease Overview

Systemic Lupus Erythematosus is a chronic inflammatory condition that affects connective tissues such as cartilage and the lining of blood vessels, which provide strength and flexibility to body structures. SLE affects multiple organs and structures, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system, and the signs and symptoms differ from person to person. SLE is one of a wide number of autoimmune disorders, which occur when the body’s immune system attacks its own tissues and organs.

Lupus flares range in severity from moderate to severe. SLE is most prevalent in women of reproductive age (often beginning at childbearing age), though lupus is becoming more widely recognised after the age of 40, particularly among Europeans.

Systemic Lupus Erythematosus Epidemiology Segmentation

The Systemic Lupus Erythematosus report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

• Systemic Lupus Erythematosus Total Diagnosed Prevalent Cases
• Systemic Lupus Erythematosus Severity-Specific Cases
• Systemic Lupus Erythematosus Gender Specific Cases
• Systemic Lupus Erythematosus Treatable Cases

For more information about epidemiology visit, Systemic Lupus Erythematosus Epidemiology

Systemic Lupus Erythematosus Treatment Landscape

The current market of SLE is majorly driven by Corticosteroids, Immunosuppressant, Antimalarials (Plaquenil) and Biologics (Rituximab, Belimumab). Nonsteroidal anti-inflammatory drugs (NSAIDs).

Hydroxychloroquine (Plaquenil) and Belimumab (Benlysta) are approved therapies for the treatment of SLE. With the approval of these therapies, the outlook for patients SLE improved from a 4-year survival rate of ~50% in 1950 to a 15-year survival rate of ~85% by 2013. New biologics targeting B cells, T cells or cytokines (especially interferon) are still going through trials raising the hope that novel therapies for patients with refractory SLE may be available soon.

Systemic Lupus Erythematosus Market

• Market Size of SLE in the 7MM was found to be USD 1,028.99 Million in 2017
• Owing to the launch of upcoming therapies, market size shall increase during forecast period (2017-2030)
• Among the 7MM, the US accounts for the 71% of the overall market size of SLE in 2017
• Among the EU-5 countries, the UK accounts for highest market size for SLE followed by Italy

Systemic Lupus Erythematosus Pipeline Therapies and Major Players

• Anifrolumab: AstraZeneca
• Baricitinib: Eli Lilly
• Lupuzor: ImmuPharma
• Cenerimod: Idorsia Pharmaceuticals
• ltILT-101: Ioo Pharma
• XmAb5871: Xencor
• BIIB059: Biogen
• Efavaleukin alfa: Amgen
• Dapirolizumab pegol: UCB Pharma/Biogen
• IFNα Kinoid: Neovacs
• Avizakimab: Boston Pharmaceuticals
• Lulizumab pegol: Bristol-Myers Squibb
• Iberdomide: Bristol-Myers Squibb

Know more about the SLE Market and Pipeline Therapies @ SLE Market and Emerging Drug Therapies

Systemic Lupus Erythematosus Market Drivers

• Increasing Awareness of the Disease
• Promising Therapeutic Approaches
• Favorable Environment for New drugs
• Current Advancements in Research and Development

Systemic Lupus Erythematosus Market Barriers

• Obstacles in SLE Pipeline success
• Hit and Trial Approach of Researchers
• Huge Economic Impact

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2017-30

Key Companies: AstraZeneca, ImmuPharma, Eli Lilly, ILTOO Pharma, Biogen, Amgen, UCB Pharma, Neovacs, Idorsia Pharmaceuticals, Boston Pharmaceuticals, Bristol-Myers Squibb, Xencor, among others. 

Key SLE Pipeline Therapies: Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), ILT-101 (ILTOO Pharma), BIIB059 (Biogen), Efavaleukin alfa (Amgen), Dapirolizumab pegol (UCB Pharma/Biogen), IFNα Kinoid (Neovacs), Cenerimod (Idorsia Pharmaceuticals), Avizakimab (Boston Pharmaceuticals), Lulizumab pegol , Iberdomide (Bristol-Myers Squibb), XmAb5871 (Xencor), and others.

SLE Market Segmentation: By Geography, By SLE therapies

Analysis: Comparative and conjoint analysis of SLE emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

For more details visit @ Systemic Lupus Erythematosus Market

Table of Contents

Get in touch with our Business executive for Pharma and Healthcare Market Assessment and Consulting 

Related Reports

 Systemic Inflammatory Response Syndrome Market

Get comprehensive historical and forecast analysis of Systemic Inflammatory Response Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as GlaxoSmithKline, AstraZeneca ,CytoSorbents Corporation, Cardinal Health, Asahi Kasei, ConvaTec, CHIESI Farmaceutici, Smith & Nephew, and Orion Corporation among others.

 Systemic Mastocytosis Market 

Get comprehensive historical and forecast analysis of Systemic Mastocytosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Mylan NV, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Novartis AG, Bayer AG, Mallinckrodt Pharmaceuticals, EPI Health, LLC, and Kaleo Inc.

 Systemic Scleroderma Market

Get comprehensive historical and forecast analysis of Systemic Scleroderma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Bayer AG.

Systemic Sclerosis Associated Interstitial Lung Disease Market Size

DelveInsight’s “Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) – Market Insights, Epidemiology and Market Forecast-2030” report. 

Diffuse Cutaneous Systemic Sclerosis (dcSSc) Market

DelveInsight’s “Diffuse cutaneous systemic sclerosis (dcSSc) – Market Insights, Epidemiology, and Market Forecast-2030” report.

Systemic Juvenile Idiopathic Arthritis Market

DelveInsight’s “Systemic Juvenile Idiopathic Arthritis (SJIA) – Market Insights, Epidemiology, and Market Forecast-2030” report.

Gene and Cell Therapies Targeting CNS Disorders Market

Get comprehensive historical and forecast analysis of Gene and Cell Therapies Targeting CNS Disorders Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novartis, Helixmith, BrainStorm Cell Therapeutics, Corestem, Ferrer Internacional others.

Acute Kidney Injury Market

DelveInsight’s “Acute Kidney Injury (AKI) – Market Insights, Epidemiology, and Market Forecast-2030” report.

Acute Renal Failure Market

DelveInsight’s “Acute Renal Failure (ARF) (Acute Kidney Injury) – Market Insights, Epidemiology, and Market Forecast-2030” report.

Anemia in CKD patients Market

DelveInsight’s “Anemia in CKD patients – Market Insights, Epidemiology, and Market Forecast-2030” report.

ABSSI Market

Sinusitis Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us 
Sandeep Joshi 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Tags: SLEMarket, SLEMarketSize, SLE, SLEPipelineTherapies See Campaign: https://www.delveinsight.com/
Contact Information:
[email protected]

Tags:
, Menafn, IPS, Reportedtimes, iCN Internal Distribution, Extended Distribution, Research Newswire, English